Candid Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Candid Therapeutics, Inc. - overview
Established
2024
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Founded in 2024 and based in California, US, Candid Therapeutics, Inc. is a biotechnology company that offers therapies for the treatment of a range of immunological conditions. In March 2026, Candid Therapeutics, Inc. raised USD 505 million in venture funding from new investors Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, Viking Global Investors, Cormorant Asset Management, Vivo Capital.
Returning investors VenBio, Foresite Capital, Soleus Capital Management, TCG Crossover Management and other unspecified investors also participated in the round. As of 2024, the company is being led by its CEO, Ken Song, CMO, Tim Lu, CFO, Arvind Kush, and CTO, Bernie Huyghe. Candid Therapeutics develops therapies for autoimmune diseases, aiming to provide effective treatments through T-cell engager antibodies. Their approach targets autoreactive B-cells by leveraging T-cells that penetrate deeper and provide more durable B-cell depletion compared to traditional antibody treatments like Rituxan® and avoids the complexities and costs associated with cell therapies.
Current Investors
OrbiMed Advisors, Polaris Partners, Venrock
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics
Website
www.candidrx.com
Verticals
Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
Candid Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Announced | Rallybio Corp | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.